{"disease":{"id":"small-cell-lung-cancer-extensive-stage","name":"small cell lung cancer extensive stage"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07472517","title":"DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":670,"lead_sponsor_name":"Boehringer Ingelheim","has_results":false},{"nct_id":"NCT05945745","title":"Molecular Analysis and Treatment Options of SCLC","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Shanghai Chest Hospital","has_results":false},{"nct_id":"NCT07400575","title":"Anlotinib in Cross-line Treatment of NSCLC and SCLC","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":350,"lead_sponsor_name":"Henan Cancer Hospital","has_results":false},{"nct_id":"NCT07005128","title":"A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":330,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT00791154","title":"QUILT-2.013: First-Line Treatment for Extensive Stage Small Cell Lung Cancer","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":213,"lead_sponsor_name":"NantCell, Inc.","has_results":true},{"nct_id":"NCT07489339","title":"MDT-Based Nursing for Small Cell Lung Cancer During Chemo-Immunotherapy","phase":"NA","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"Shanxi Province Cancer Hospital","has_results":false},{"nct_id":"NCT07227597","title":"A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":170,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT03911219","title":"Impact of eHealth Monitoring on Overall Survival in Patients With Metastatic NSCLC / Extensive-stage SCLC / Advanced TNBC Under First-line Treatment With Atezolizumab Plus Chemotherapy","phase":"","overall_status":"COMPLETED","enrollment_count":154,"lead_sponsor_name":"iOMEDICO AG","has_results":false},{"nct_id":"NCT06739928","title":"Irinotecan Liposome (II) or Etoposide Combined With Adebrelimab and Carboplatin in the Treatment of ES-SCLC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"Guangzhou Institute of Respiratory Disease","has_results":false},{"nct_id":"NCT06030258","title":"IN10018 Combination Therapy in Treatment-naïve ES-SCLC","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"InxMed (Shanghai) Co., Ltd.","has_results":false},{"nct_id":"NCT06982287","title":"A Retrospective Real-World Study on the Efficacy and Safety of Anlotinib Hydrochloride Combined With Immunotherapy Maintenance Therapy Following Standard Chemoimmunotherapy for ES-SCLC (ALTER-L059)","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":100,"lead_sponsor_name":"Yong Fang","has_results":false},{"nct_id":"NCT06648200","title":"Toripalimab and JS004 Combined With Platinum-based Chemotherapy for Relapsed and Extensive-stage Small Cell Lung Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":100,"lead_sponsor_name":"Shanghai Pulmonary Hospital, Shanghai, China","has_results":false},{"nct_id":"NCT05903092","title":"MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer","phase":"PHASE2","overall_status":"SUSPENDED","enrollment_count":84,"lead_sponsor_name":"Hirva Mamdani","has_results":false},{"nct_id":"NCT03059667","title":"Immunotherapy as Second-line in Patient With Small Cell Lung Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":73,"lead_sponsor_name":"Intergroupe Francophone de Cancerologie Thoracique","has_results":false},{"nct_id":"NCT04462276","title":"Thoracic RadiothErapy With Atezolizumab in Small Cell lUng canceR Extensive Disease","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":68,"lead_sponsor_name":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","has_results":false},{"nct_id":"NCT03994744","title":"Assessing Safety and Efficacy of Sintilimab and Metformin Combination Therapy in SCLC","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":68,"lead_sponsor_name":"Hunan Cancer Hospital","has_results":false},{"nct_id":"NCT06851819","title":"Tislelizumab in Combination with Chemotherapy ± Radiotherapy for Extensive-Stage Oligometastatic Small Cell Lung Cancer.","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":64,"lead_sponsor_name":"Hebei Medical University Fourth Hospital","has_results":false},{"nct_id":"NCT07480213","title":"Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Beijing Biotech","has_results":false},{"nct_id":"NCT04659785","title":"A Study of Fluzoparib Combined With Apatinib as Second-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer（FA-ES-SCLC）","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":53,"lead_sponsor_name":"Tianjin Medical University Second Hospital","has_results":false},{"nct_id":"NCT05068232","title":"Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":49,"lead_sponsor_name":"University of Chicago","has_results":false},{"nct_id":"NCT05384015","title":"Study of Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-stage Small Cell Lung Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":46,"lead_sponsor_name":"Fundación GECP","has_results":false},{"nct_id":"NCT07139990","title":"Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM)","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":45,"lead_sponsor_name":"University of Texas Southwestern Medical Center","has_results":false},{"nct_id":"NCT06554535","title":"Efficacy and Safety of Serplulimab With Chemotherapy and Aspirin in Untreated Extensive-Stage Small Cell Lung Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":43,"lead_sponsor_name":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","has_results":false},{"nct_id":"NCT05066945","title":"Application of ctDNA in the Evaluation of Curative Effect and Prognosis of SCLC Patients","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":40,"lead_sponsor_name":"Xiangya Hospital of Central South University","has_results":false},{"nct_id":"NCT03755115","title":"SHR-1210 Combined With Epirubicin in the Treatment of Extensive Disease Small Cell Lung Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"Henan Cancer Hospital","has_results":false},{"nct_id":"NCT06429696","title":"PD-L1 Inhibitor Combined With Apatinib as First-line Maintenance Treatment for Extensive-stage Small Cell Lung Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Nanfang Hospital, Southern Medical University","has_results":false},{"nct_id":"NCT07061535","title":"Sintilimab Combined With Tafolecimab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":40,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT07339059","title":"Phase II Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":35,"lead_sponsor_name":"Bindu R Potugari","has_results":false},{"nct_id":"NCT06786312","title":"A Single-arm, Multicenter, Prospective Phase II Clinical Study of Apatinib in Combination With Adebrelimab and EC Regimen in the First-line Treatment of Extensive Small Cell Lung Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":34,"lead_sponsor_name":"Fujian Cancer Hospital","has_results":false},{"nct_id":"NCT06187740","title":"Thoracic Consolidation Radiotherapy for ES-SCLC Treated With Chemo-immunotherapy","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":28,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT06348797","title":"Phase I Clinical Study of α-PD-L1/DLL3 CAR-T in Patients With R/R SCLC","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":28,"lead_sponsor_name":"Sichuan University","has_results":false},{"nct_id":"NCT07358676","title":"A Study of Bemotuzumab Plus Chemotherapy and Anlotinib Induction Followed by Bemotuzumab, Anlotinib and Consolidative Thoracic Radiotherapy in Extensive-Stage Small Cell Lung Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":25,"lead_sponsor_name":"Tianjin Medical University Cancer Institute and Hospital","has_results":false},{"nct_id":"NCT03253068","title":"Pembrolizumab Plus Amurubicin in Patients With Refractory Small-cell Lung Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":25,"lead_sponsor_name":"Wakayama Medical University","has_results":false},{"nct_id":"NCT03913455","title":"Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell Lung Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"Shadia Jalal, MD","has_results":true},{"nct_id":"NCT04967625","title":"A Phase II Study of Sintilimab Combined With Anlotinib in Treatment of ED-SCLC","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":23,"lead_sponsor_name":"Zhejiang Cancer Hospital","has_results":false},{"nct_id":"NCT03043599","title":"Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":21,"lead_sponsor_name":"H. Lee Moffitt Cancer Center and Research Institute","has_results":true},{"nct_id":"NCT03325816","title":"Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":9,"lead_sponsor_name":"Georgetown University","has_results":true},{"nct_id":"NCT00003496","title":"Antineoplaston Therapy in Treating Patients With Recurrent or Extensive-Stage Small Cell Lung Cancer","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":4,"lead_sponsor_name":"Burzynski Research Institute","has_results":false},{"nct_id":"NCT05027867","title":"KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"Kartos Therapeutics, Inc.","has_results":false},{"nct_id":"NCT06939036","title":"Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"Ariceum Therapeutics GmbH","has_results":false},{"nct_id":"NCT03166254","title":"Personalized Therapeutic Anti-tumor Vaccine With Pembrolizumab and Standard of Care Chemotherapy in Squamous Non-Small Cell Lung Cancer and Extensive Stage Small Cell Lung Cancer","phase":"PHASE1","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Washington University School of Medicine","has_results":false}],"total":41},"guidelines":[],"source":"Drug Landscape verified database"}